Related Experiment Videos

GPI-anchored molecule-like protein (GML) expression in non-small cell lung cancer (NSCLC)

T Komiya1, T Hirashima, M Kikui

  • 1Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Japan.

Anticancer Research
|January 11, 2000
PubMed
Abstract

Insights

GPI-anchored molecule-like protein (GML) expression is infrequent in non-small cell lung cancer (NSCLC) and appears to be regulated independently of the p53 gene, contrary to previous findings in other cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • GPI-anchored molecule-like protein (GML) is a novel p53 target.
  • GML mRNA expression correlates with drug sensitivity in esophageal cancer.
  • GML expression was previously thought to be p53-dependent.

Purpose of the Study:

  • To investigate the relationship between GML mRNA expression and p53 gene status in non-small cell lung cancer (NSCLC).

Main Methods:

  • Analysis of 24 NSCLC cell lines.
  • Reverse transcription-polymerase chain reaction (RT-PCR) for GML mRNA detection.
  • Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and DNA sequencing for p53 gene status.

Main Results:

  • GML mRNA expression was detected in only 3 out of 24 NSCLC cell lines.
  • One of the GML-expressing cell lines harbored a p53 gene mutation (codon 245).
  • This contrasts with previous studies suggesting p53-dependent GML expression.

Conclusions:

  • GML mRNA expression is infrequent in NSCLC.
  • GML mRNA expression in NSCLC is regulated in a p53-independent manner.

Related Concept Videos